Abstract
Purpose: Our goal was to investigate the safety, effectiveness, and feasibility for the practicing physician of stepwise and low-dose administration of FSH in WHO group II anovulatory infertile women.
Methods: Infertile female patients (n=234) suffering from WHO group II anovulation, and who failed to became pregnant with clomiphene citrate, were included in a multicenter, prospective, clinical study of treatment with a protocol of chronic low-dose and small incremental rises with urinary purified or highly purified FSH. Follicular development was monitored with ultrasonographic scans.
Results: The 234 patients received a total of 534 cycles of treatment, for a mean number of 2.3 treated cycles per patient. hCG was withheld in 65 (12.2%) cyles because of no response and in 28 (5.2%) cycles because of hyperresponse. Of the remaining 441 cycles, 419 (95%) were ovulatory, and in 198 (47.3%) of these cycles a single dominant follicle developed. There were 93 pregnancies (39.7% per patient), for a cycle fecundity rate of 17.4%. Cumulative conception rate after two treated cycles was 33.5%. There were 14 (15%) pairs of twins and 10 (10.8%) spontaneous miscarriages. The prevalence of complications was low with no cases of severe OHSS. Basal LH/FSH ratio was significantly higher in the pregnant group of patients than in nonpregnant women.
Conclusions: Stepwise and chronic low-dose administration of FSH is a safe and effective method for treatment of WHO group II anovulatory infertility, mainly in those patients having high LH/FSH ratios.
Similar content being viewed by others
References
Hill GA: The ovulatory factor and ovulation inducement.In Gynecologic Endocrinology and Infertility, AC Wentz, CM Herbert III, GA Hill (eds). Baltimore, Williams and Wilkins, 1988, pp 147–160
WHO Scientific Group Report (B Lunenfeld, Chairman): Agents stimulating gonadal function in the human. WHO Techn Rep Ser 1973;514:1–28
Speroff L, Glass RH, Kase NG: Clinical Gynecologic Endocrinology and Infertility, 5th ed. Baltimore, Williams and Wilkins, 1994
Wu CH: Monitoring of ovulation induction: Fertil Steril 1978;30:617–630
Garcea N, Campo S, Panetta V, Venneri M, Siccardi P, Dargenio R, De Tomasi F: Induction of ovulation with purified urinary follicle-stimulating hormone in patients with polycystic ovarian syndroem. Am J Obstet Gynecol 1985;151:635–649
Buvat JB, Buvat-Herbaut M, Marcolin G, Dehaene JL, Verbecq P, Renouard O: Purified follicle-stimulating hormone in polycystic ovary syndrome: slow administration is safer and more effective. Fertil Steril 1989;52:553–559
Sagle MA, Hamilton-Fairley D, Kiddy DS, Franks S: A comparative, randomized study of low dose human menopausal gonadotropin and follicle-stimulating hormone in women with polycystic ovarian syndrome. Fertil Steril 1991;55:56–60
Shoham Z, Patel A, Jacobs HS: Polycystic ovarian syndrome: Safety and effectiveness of stepwise and low dose administration of purified follicle stimulating hormone. Fertil Steril 1991;55:1051–1056
Hamilton-Fairley D, Kiddy D, Watson H, Sagle M, Franks S: Low-dose gonadotrophin therapy for induction of ovulation in 100 women with polycystic ovary syndrome. Hum Reprod 1991;6:1095–1099
Homburg R, Levy T, Ben-Rafael Z: A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome. Fertil Steril 1995;63:729–733
Ferriman D, Gallwey JD: Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440–1447
Le Cotonnec JY, Porchet HC, Beltrami V, Howles C: Comparative pharmacokinetics of two urinary human follicle stimulating hormone preparations in healthy female and male volunteers. Hum Reprod 1993;8:1604–1611
Howles CM, Loumaye E, Giroud D, Luyet G: Multiple follicular development and ovarian steroidogenesis following subcutaneous administration of a highly purified urinary FSH preparation in pituitary desensitized women undergoing IVF: A multicentre European phase III study. Hum Reprod 1994;9:424–430
Flamigni C, Venturoli S, Dal Patro L, Porcu E: Purified FSH: Characteristics and applications.In Ovulation Induction: Basis Science and Clinical Advances, M Filicori, C Flamigni (eds). Amsterdam, Excerpta Medica, 1993, pp 125–134
Golan A, Ron-El R, Herman A, Soffer Y, Weinraub Z, Caspi E: Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989;44:430–440
Adams J, Polson DW, Franks S: Prevalence of polycystic ovaires in women with anovulation or idiopathic hirsutism. Br Med J 1986;293:355–359
Franks S: Polycystic ovary syndrome: A changing perspective. Clin Endocrinol 1989;51:87–120
Pache TD, de Jong FH, Hop WC, Fauser BCJM: Association between ovarian changes assessed by transvaginal sonography and clinical and endocrine signs of the polycystic ovary syndrome. Fertil Steril 1993;59:544–549
Seibel MM, Kamrava MM, MacArdle C, Taymor ML: Treatment of polycystic ovary disease with chronic low-dose follicle stimulating hormone: Biochemical changes and ultrasound correlation. Int J Fertil 1984;29:39–43
Blumenfeld Z, Nahhas F: Luteal dysfunction in ovulation induction: The role of repetitive human chorionic gonadotropin supplementation during the luteal phase. Fertil Steril 1988;50: 403–407
Shoham Z, Jacobs HS, Insler V: Luteinizing hormone: Its role, mechanism of action, and detrimental effects when hypersecreted during the follicular phase. Fertil Steril 1993;59:1153–1161
Rodgers M, McLoughlin J, Peers N, Anderson J, Woods P, Mitchell GG, Robertson WR: Accumulation of human chorionic gonadotrophin in the serum patients during in-vitro fertilization treatment cycles with Pergonal. Hum Reprod 1994;9:638–642
Hughes EG, Fedorkow DM, Daya S, Sagle MA, Van de Koppel P, Collins JA: The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril 1992;58:888–896
Schoot DC, Pijlman B, Stilnen T, Fauser BCJM: Effects of gonadotrophin releasing hormone agonist addition to gonadotrophin induction of ovulation in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 1992;45:53–58
Abu-Heija AT, Fleming R, Yates RWS, Coutts JRT: Pregnancy outcome following exposure to gonadotrophin-releasing hormone analogue during early pregnancy: Comparisons in patients with normal and elevated luteinizing hormone. Hum Reprod 1995;10:3317–3319
Seibel MM: Follicle-stimulating hormone for polycystic ovary syndrome.In Ovulation Induction MM Seibel, RE Blackwell (eds.). New York, Raven Press, 1994, pp 135–144
Jewelewicz R, Gindoff PR: Induction of ovulation—Past, present and future. Gynecol Obstet Invest 1988;26:89–103
Hillier SG: Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Hum Reprod 1994;9:188–191
Author information
Authors and Affiliations
Additional information
(on behalf of the multicenter trialists: P. ALVAREZ, Maternidad Santa Cristina, Madrid; J. M. BAJO, Clínica Belén, Madrid; E. BOSCH, Hospital La Fe, Valencia; I. BRUNA, Hospital de Móstoles, Madrid; P. CABALLERO, Hospital Ramón y Cajal, Madrid; J. CALAF, Hospital de la Santa Creu i Sant Pau, Barcelona; I. CANO, Hospital Carlos Haya, Málaga; E. CARRILLO, Hospital Ruber Internacional, Madrid; J. A. DUQUE, Hospital Miguel Servet, Zaragoza; G. FOLGUERA, Hospital de Getafe, Madrid; A. DE LA FUENTE, Fundación Jiménez Díaz, Madrid; C. JIMÉNEZ, Hospital Na Sra. de Sonsoles, Avila; G. LAGUENS, Madrid: E. LÓPEZ, Hospital Virgen de la Arrixaca, Murcia; A. LOZANO, Hospital Provincial, Toledo; A. MATARRANZ, Hospital de Guadalajara, Guadalajara; C. MORENO, IMGI, Madrid; J. NAVA, Hospital Gregorio Marañón, Madrid; M. SANCHIS, Madrid; E. TEMPRANO, Hospital Juan Canalejo, La Coruña; G. VENTURA, Madrid)
Rights and permissions
About this article
Cite this article
Balasch, J., Tur, R. & Peinado, J.A. The safety and effectiveness of stepwise and low-dose administration of follicle stimulating hormone in WHO group II anovulatory infertile women: Evidence from a large multicenter study in Spain. J Assist Reprod Genet 13, 551–556 (1996). https://doi.org/10.1007/BF02066607
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02066607